Akari Therapeutics PLC (AKTX) Earns “Buy” Rating from Canaccord Genuity
Akari Therapeutics PLC (NASDAQ:AKTX)‘s stock had its “buy” rating reiterated by equities researchers at Canaccord Genuity in a research note issued on Friday. They currently have a $15.00 price target on the biopharmaceutical company’s stock. Canaccord Genuity’s price target would suggest a potential upside of 83.37% from the company’s current price.
The analysts wrote, “Date and time of first dissemination: September 21, 2017, 23:12 ET Date and time of production: September 21, 2017, 20:41 ET Target Price / Valuation Methodology: Impax Laboratories – IPXL Our $19 price target is derived from a blend of DCF (7.7% WACC, +1% terminal growth) and a 9.2x forward EV/EBITDA on our 2018 estimates. IPXL shares currently trade around 8x our 2018 EV/EBITDA compared to a group average of around 9.2x. We think a group average EV/EBITDA valuation is warranted because of potential P&L leverage growing profitability faster than revenue which warrants a premium, a premium warranted for the company’s well-respected leadership offset by a discount to the group for relatively low expected top-line growth and a low-duration FTF/FTM based generics pipeline.””
Other equities research analysts also recently issued research reports about the company. William Blair raised Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a report on Friday. Chardan Capital reissued a “neutral” rating on shares of Akari Therapeutics PLC in a report on Sunday, September 17th. Zacks Investment Research raised Akari Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, ValuEngine raised Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $8.00.
Akari Therapeutics PLC (NASDAQ AKTX) traded down 6.41% during midday trading on Friday, hitting $8.18. The stock had a trading volume of 3,632,740 shares. The company’s market capitalization is $96.33 million. The company’s 50-day moving average price is $4.17 and its 200 day moving average price is $7.23. Akari Therapeutics PLC has a 52 week low of $3.18 and a 52 week high of $22.20.
An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd acquired a new position in Akari Therapeutics PLC (NASDAQ:AKTX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned approximately 0.51% of Akari Therapeutics PLC at the end of the most recent quarter. 26.85% of the stock is currently owned by institutional investors.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.